Complexity, cost, and content - three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing, Clin Chem Lab Med. 2019 Dec 13, pii: /j/cclm.ahead-of-print/cclm-2019-0977/cclm-2019-0977.xml.
ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors, ATVB. 2019 Aug 8:ATVBAHA119312723. doi: 10.1161/ATVBAHA.119.312723
Top-down mass spectrometric immunoassay for human insulin and its therapeutic analogs, J Proteomics. 2018 Mar 20;175:27-33
Mass spectrometric studies of apolipoprotein proteoforms and their role in lipid metabolism and type 2 diabetes, Proteomes. 2017 Oct 15;5(4). pii: E27. doi: 10.3390/proteomes5040027
Human proteoforms as new targets for clinical mass spectrometry protein tests, Expert Rev Proteomics.2017 Aug;14(8):691-699.
Translating Mass Spectrometry-Based Protein Assays And The Challenging Road Ahead: Post-Translationally Modified Proteins As Biomarker Targets For Clinical MS Protein Tests. 5th EFLM-UEMS European Joint Congress on Laboratory Medicine, October 10-13, 2018, Antalya, Turkey.
Translating MS protein assays into the clinic: The challenging road ahead, and the potential of posttranslationally modified proteins as new biomarker targets for clinical MS protein tests. HUPO 2017, September 17-21, Dublin, Ireland.